

82W 1635

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	08/480,472	
	Filing Date	June 6, 1995	
	First Named Inventor	Sherrol McDonough	
	Art Unit	1635	
	Examiner Name	Marschel, A.	
Total Number of Pages in This Submission	43	Attorney Docket Number	GP034-03.DV1

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 2 Copies of Cited References (24 pgs.); Form PTO/SB/08 in duplicate (8 pgs.); and Form PTO-1449 in duplicate (6 pgs.).
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm Name	Gen-Probe Incorporated		
Signature			
Printed name	Charles B. Cappellari		
Date	January 19, 2005	Reg. No.	40,937

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Charles B. Cappellari	Date	January 19, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (10-04)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Examiner Name	Marschel, A.
Art Unit	1631
Attorney Docket No.	GP034-03.DV1

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:

Deposit Account Number

07-0835

Deposit Account Name

Gen-Probe Incorporated

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	790	2001	395	Utility filing fee	
1002	350	2002	175	Design filing fee	
1003	550	2003	275	Plant filing fee	
1004	790	2004	395	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	-20** =	X	
Independent Claims	-3** =	X	
Multiple Dependent			

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	88	2201	44	Independent claims in excess of 3
1203	300	2203	150	Multiple dependent claim, if not paid
1204	88	2204	44	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	430	2252	215	Extension for reply within second month	
1253	980	2253	490	Extension for reply within third month	
1254	1,530	2254	765	Extension for reply within fourth month	
1255	2,080	2255	1,040	Extension for reply within fifth month	
1401	340	2401	170	Notice of Appeal	
1402	340	2402	170	Filing a brief in support of an appeal	
1403	300	2403	150	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,370	2501	685	Utility issue fee (or reissue)	
1502	490	2502	245	Design issue fee	
1503	660	2503	330	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00)

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)

Charles B. Cappellari

Registration No.
(Attorney/Agent)

40,937

Telephone 858 410-8927

Signature

Date


January 19, 2005

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Group Art Unit: 1631
)	
McDONOUGH <i>et al.</i>)	Examiner: Marschel, A.
)	
Serial No. 08/480,472)	Atty. Docket No. GP034-03.DV1
)	
Filed: June 6, 1995)	Confirmation No. 9286
)	
For: NUCLEIC ACID SEQUENCE)	
AMPLIFICATION)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants bring to the Examiner's attention the references listed on the enclosed Form PTO/SB/08 and Form PTO-1449 from sister application Serial No. 08/479,105 (two copies of each) for consideration in connection with the examination of the above-identified application. A copy of each identified reference which was not previously cited during the prosecution of ancestor application Serial Nos. 07/855,732 and 08/345,861 is enclosed herewith.

This Information Disclosure Statement is being submitted under 37 C.F.R. § 1.97(c) more than three months from the filing date of the instant application and after the mailing date of a first Office action on the merits but before the mailing date of either a final action or notice of allowance.

Please charge the fee due under 37 C.F.R. § 1.17(p) to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.

IDS


Serial No. 08/480,472
Atty. Docket No. GP034-03.DV1

Applicants respectfully request that the Examiner indicate consideration of the cited references by returning copies of the enclosed Forms PTO/SB/08 and PTO-1449 with the Examiner's initials or other appropriate marks.

Certificate of Mailing

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being deposited on the date indicated below with the U.S. Postal Service as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Respectfully submitted,



Dated: January 19, 2005

By:

Charles B. Cappellari
Registration No. 40,937
Attorney for Applicants

GEN-PROBE INCORPORATED
Patent Department
10210 Genetic Center Drive
San Diego, California 92121
PH: (858) 410-8927
FAX: (858) 410-8928

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Art Unit	1631
Examiner Name	Marschel, A.
Attorney Docket Number	GP034-03.DV1

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY			
		WO-A-88 03957	06-02-1988	Gen-Probe Inc.		
		WO-A-93 04201	03-04-1993	Amoco Corp.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Art Unit	1631
Examiner Name	Marschel, A.
Attorney Docket Number	GP034-03.DV1

Sheet

2

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Brewer, et al., "Mechanistic Independence of Avian Myeloblastosis Virus DNA Polymerase and Ribonuclease H," Dec. 1974, J. Virol., 14(6):1494-1502, ASM, USA.	
		Champoux, et al., "Mechanism of RNA Primer Removal by the RNase H Activity of Avian Myeloblastosis Virus Reverse Transcriptase," Mar. 1984, J. Virol., 49(3):686-691, ASM, USA.	
		Collett, et al., "In Vitro Transcription of 70S RNA by the RNA-Directed DNA Polymerase of Rouse Sarcoma Virus: Lack of Influence by RNase H," Jan. 1976, J. Virol. 17(1):291-5, PMID: 54443, ASM, USA.	
		Crouch, R.J., "Ribonuclease H: from discovery to 3D structure," Sep. 1990, New Biol., 2(9):771-7, PMID: 2177653.	
		Day, R., "How to Write and Publish a Scientific Paper," 2nd Ed., Philadelphia: ISI Press, 1983, p.170.	
		Fahy, et al., "Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR," Aug. 1991, PCR Methods Appl., 1(1):25-33, PMID: 1842917.	
		Grandgenett, et al., "Different Mode of Action of Ribonuclease H in Purified alpha and alpha beta Ribonucleic Acid-Directed Deoxyribonucleic Acid Polymerase from Avian Myeloblastosis Virus" Aug. 25, 1974, J. Biol. Chem., 249(16):5148-5152, USA.	
		Kacian, et. al., "Synthesis of extensive, possibly complete, DNA copies of poliovirus RNA in high yields and at high specific activities," July 1976, Proc. Natl. Acad. Sci., 73(7):2191-2195, USA.	
		Kacian, et al., "Anticomplementary nature of smaller DNA produced during synthesis of extensive DNA copies of poliovirus RNA," October 1976, Proc. Natl. Acad. Sci., 73(10):3408-3412, USA.	
		Keller, et al., "Degradation of DNA RNA Hybrids by Ribonuclease H and DNA Polymerase of Cellular and Viral Origin," November 1972, Proc. Natl. Acad. Sci. 69(11):3360-3364, USA.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

4

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Art Unit	1631
Examiner Name	Marschel, A.
Attorney Docket Number	GP034-03.DV1

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Maniatis, et al., Molecular Cloning, 1982, Cold Spring Harbor, N.Y.: Cold Spring Harbor Press, pp. 128, 213-214.	
		Marcus, et al., "Reverse Transcriptase-Associated RNase H Activity II. Inhibition by Natural and Synthetic RNA," Sept. 1978, J. Virol. 27(3):576-581, ASM, USA.	
		Modak, et al., "Specific Inhibition of DNA Polymerase-Associated RNase H by DNA," Apr. 1977, J. Virol., 22(1):243-246, ASM, USA.	
		Moelling, K., "Characterization of reverse transcriptase and RNase H from friend-murine leukemia virus," Nov. 1974, Virology, 62(1):46-59, PMID: 4138103.	
		Myers, et al., "RNA primer used in synthesis of anticomplementary DNA by reverse transcriptase of avian myeloblastosis virus," March 1980, Proc. Natl. Acad. Sci., 77(3) 1316-1320, USA.	
		Myers, et al., "Sodium pyrophosphate inhibition of RNA-DNA hybrid degradation by reverse transcriptase," Nov. 1978, Proc. Natl. Acad. Sci., 75(11):5329-5333, USA.	
		Myers, et al., "Synthesis of full-length DNA copies of avian myeloblastosis virus RNA in high yields," July 1977, Proc. Natl. Acad. Sci., 74(7):2840-2843, USA.	
		Resnick, et al., "Involvement of Retrovirus Reverse Transcriptase-Associated RNase H in Initiation of Strong Stop (+) DNA Synthesis and the Generation of the Long Terminal Repeat," Sept. 1984, J. Virol. 51(3):813-821, ASM, USA.	
		Rogall, et al., "Differentiation of Mycobacterium species by direct sequencing of amplified DNA," Sept. 1990, J. Gen. Microbiol., 136(Pt. 9):1915-1920, PMID: 2283506.	
		Srivastava, et al., "Reverse transcriptase-associated RNase H. Part IV. Pyrophosphate does not inhibit RNase H activity of AMV DNA polymerase," Dec. 14, 1979, Biochem. Biophys. Res. Commun., 91(3):892-899, PMID: 93479.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Art Unit	1631
Examiner Name	Marschel, A.
Attorney Docket Number	GP034-03.DV1

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wintersberger, U., "Ribonucleases H of retroviral and cellular origin," 1990, Pharmacol. Ther., 48(2):259-280 PMID: 1963496.	
		Wohrl, et al., "Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities," Aug. 5, 1991, J. Mol. Biol., 220(3):801-818, PMID: 1714505.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
213/067SERIAL NO.
08/479,105APPLICANT:
Diane L. McAllister et al.FILING DATE:
June 6, 1995

GROUP:

Citations for Divisional Application
Serial No. 08/480,472, Filed June 6, 1995
Attorney Docket No. GP034-03.DV1
Page 1 of 3

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA	4 6 8 3 2 0 2	07/28/87	Mullis			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	AB 9 1 0 1 3 8 4	07.02.91	PCT/WO (Kacian and Fultz)			
	AC 0 4 0 8 2 9 5	16.01.91	EPO (Kacian and Fultz)			
	AD 0 4 3 9 1 8 2	25.01.91	EPO (Backman et al.)			
	AE 9 2 0 7 9 5 7	14.05.92	EPO (Cimino et al.)			
	AF 9 2 2 2 6 6 3	23.12.92	WO/PCT (Schuster and Beminger)			
	AG 0 5 8 7 2 6 6	06.05.93	EPO (Kacian et al.)			
	AH 5 5 9 7 0 9	24.02.88	Canada (Malek and Davey)			
	AI 0 3 2 9 8 8 2	30.08.89	EPO (Davey and Malek)			
	AJ 0 3 7 3 9 6 0	20.07.90	EPO (Gingeras)			
	AK 8 7 0 6 2 7 0	22.10.87	WO/PCT (Chu et al.)			
	AL 8 9 0 1 0 5 0	09.02.89	WO/PCT (Burg et al.)			
	AM 9 0 1 4 4 3 9	29.11.90	WO/PCT (Kramer and Lizardi)			
	AN 0 3 0 0 7 9 6	25.01.89	EPO (Becker et al.)			
	AO 8 8 1 0 3 1 5	29.12.88	WO/PCT (Gineras et al.)			
	AP 0 4 6 1 0 4 5	07.06.91	EPO (Guesdon and Thierry)			
	AQ 2 6 5 9 0 8 6	02.03.90	France (Brisson-Noel)			
	AR 2 6 5 1 5 0 5	06.09.89	France (Guesdon et al.)			
	AS 9 1 1 5 6 0 1	04.04.91	WO/PCT (Shuldiner and Roth)			
	AT 0 3 9 8 6 7 7	16.05.90	EPO (Wirth and Patel)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Bethesda Research Laboratories Catalogue and Reference Guide, Bethesda Research Laboratories, Bethesda, MD (1988) p. 37
AB	Both et al., "A general strategy for cloning double-stranded RNA: nucleotide sequence of the Simian-11 rotavirus gene 8," <u>Nucleic Acids Research</u> 10:7075 (1982)
AC	Cashdollar et al., "Cloning the Double-stranded RNA Genes of a Reovirus: Sequence of the cloned S2 gene," <u>Proc. Natl. Acad. Sci. USA</u> 79:7644-7648 (1982)


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



ATTY. DOCKET NO.
213/067

SERIAL NO.
08/479,105

APPLICANT:
Diane L. McAllister et al.

FILING DATE:
June 6, 1995

GROUP:

Citations for Divisional Application
Serial No. 08/480,472, Filed June 6, 1995
Attorney Docket No. GP034-03.DV1
Page 2 of 3

AD	Cox et al., "The 16S ribosomal RNA of <i>Mycobacterium leprae</i> contains a unique sequence which can be used for identification by the polymerase chain reaction," <u>J. Med. Microbiol.</u> , 35:284-290 (1991)
AE	European Search Report for Application No. 90307503.4 dated 7/21/91
AF	Golomb and Grandgenett, "Endonuclease Activity of Purified RNA-directed DNA Polymerase from Avian Myeloblastosis Virus," <u>The Journal of Biological Chemistry</u> 254:1606-1613 (1979)
AG	Grachev et al., "Oligonucleotides complementary to a promoter over the region -8... +2 as transcription primers for <i>E. coli</i> RNA polymerase," <u>Nucleic Acids Research</u> 12:8509 (1984)
AH	Guatelli et al., "Isothermal, <i>in vitro</i> amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," <u>Proc. Natl. Acad. Sci. USA</u> 87:1874-1878 (1990)
AI	Gubler, <u>Guide to Molecular Cloning Techniques</u> , Academic Press, NY, NY (1987) p. 330
AJ	Hayes, "The Genetics of Bacteria and their Viruses," John Wiley & Sons Inc., 2nd ed.:239-257, New York (1964)
AK	Joyce, "Amplification, Mutation and Selection of Catalytic RNA," <u>Gene</u> , 82:83-87 (1989)
AL	Khorana, "Total Synthesis of a Gene," <u>Science</u> , 203:614-25 (1979)
AM	Krug and Berger, "Ribonuclease H activities associated with viral reverse transcriptases are endonucleases," <u>Proc. Natl. Acad. Sci. USA</u> 86:3539-3543 (1989)
AN	Krug & Berger, "First-Strand cDNA Synthesis Primed with Oligo(dT)," (Methods in Enzymology) <u>Guide to Molecular Cloning Techniques</u> , Berger and Kimmel, eds., (Academic Press:NY, 1987) Vol. 152, pp. 316-325
AO	Kupper et al., "Promoter-dependent transcription of TRNA ¹ genes using DNA fragments produced by restriction enzymes," <u>Proc. Natl. Acad. Sci. USA</u> 72:4754 (1975)
AP	Kwoh et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format," <u>Proc. Natl. Acad. Sci. USA</u> 86:1173-1177 (1989)
AQ	Leis et al., "Mechanism of Action of the Endonuclease Associated with the $\alpha\beta$ and $\beta\beta$ Forms of Avian RNA Tumor Virus Reverse Transcriptase," <u>Journal of Virology</u> 45:727-739 (1983)
AR	Lomonosoff, et al., "The Location of the First AUG Condons in Cowpea Mosaic Virus RNAs," <u>Nucleic Acids Research</u> , 10,16:4861-72 (1982)
AS	Lowary et al., "A Better Way to Make RNA for Physical Studies," <u>Structure & Dynamics of RNA</u> , Nato ASI Series Knippenberg, eds. (New York: Plenum Press, 1986) Vol. 110
AT	Milligan et al., "Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates," <u>Nucleic Acids Research</u> 15:8783-98 (1987)
AU	Mullis and Faloona, "Specific Synthesis of DNA <i>in Vitro</i> via a Polymerase-Catalyzed Chain Reaction," <u>Methods in Enzymology</u> , 155:355-349 (1987)
AV	Murakawa et al., "Direct Detection of HIV-1 RNA from AIDS and ARC Patient Samples," <u>DNA</u> , 7:287-295, 1988
AW	Okayama and Berg, "High-Efficiency Cloning of Full-Length cDNA," <u>Molecular and Cellular Biology</u> 2:161-170, 1982.
AX	Oyama et al., "Intrinsic Properties of Reverse Transcriptase in Reverse Transcription," <u>J. Biol. Chem.</u> 264:18808-18817 (1989)

EXAMINER:

DATE CONSIDERED:


EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
213/067SERIAL NO.
08/479,105APPLICANT:
Diane L. McAllister et al.FILING DATE:
June 6, 1995

GROUP:

Citations for Divisional Application
Serial No. 08/480,472, Filed June 6, 1995
Attorney Docket No. GP034-03.DV1
Page 3 of 3

AY	Rossi et al., "An Alternate Method for Synthesis of Double-stranded DNA segments," <u>L Biol. Chem.</u> 257:9226 (1982)
AZ	Stent, "Molecular Biology of Bacterial Viruses," W.H. Freeman & Company, 157-63, San Francisco (1963)
BA	Tyagi et al., <u>Trop. Med. Parasitol.</u> 41:294-296 (1990)
BB	Watson and Crick, "Molecular Structure of Nucleic Acids," <u>Nature</u> , April 25, 1953, p. 737
BC	Watson & Crick, "Genetical Implications of the Structure of Deoxyribonucleic Acid," <u>Nature</u> , 171:964-967 (1953)
BD	Wilk et al., "Backbone-modified oligonucleotides containing a butaneodiol-1,3 moiety as a 'vicarious segment' for the deoxyribosyl moiety - synthesis and enzyme studies," <u>Nucleic Acids Research</u> 18:2065-2068 (1990)
BE	Zoller and Smith, "Oligonucleotide-Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors," <u>Methods in Enzymology</u> , 100:468-500 (1983)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.